Medtronic plans to buy SPR Therapeutics for $650 million to expand pain treatment options

Medtronic

Medtronic

MDT

0.00

May 20 (Reuters) - Medical device maker Medtronic MDT.N said on Wednesday it plans to acquire privately held SPR Therapeutics for about $650 million in cash, expanding its portfolio of treatments for chronic pain.

  • The deal gives Medtronic access to SPR's SPRINT system, a 60-day therapy designed to provide pain relief without requiring a permanent implant.

  • SPR Therapeutics is focused on non-opioid, non-surgical, minimally invasive pain management solutions.

  • Medtronic said the acquisition will help it reach more patients with less invasive pain relief options.

  • The deal is expected to close in the first half of Medtronic's fiscal 2027, which began on April 25, subject to regulatory approvals.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.